High-dose ziprasidone-induced acute dystonia.
There are few clinical data describing the relative risks of extrapyramidal symptoms (EPS) at higher doses of ziprasidone (i.e., greater than 160 mg/day) when compared to lower doses. We report on a patient who displayed no EPS with ziprasidone 160 mg/day for several months, but did display marked, acute dystonic reactions on ziprasidone 240 mg/day. The observations from the present case indicate that high-dose, ziprasidone-induced acute dystonia may occur even if no such side effects have been experienced at doses up to and including 160 mg/day.
Rosenfield
Paul J
PJ
Department of Psychiatry, College of Physicians and Surgeons, Columbia University, and New York State Psychiatric Institute, 1051 Riverside Drive, Box 109, New York, NY 10032, USA.
Girgis
Ragy R
RR
Gil
Roberto
R
D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D004421:Dystonia / Q000139:chemically induced*; D005260:Female; D006801:Humans; D010879:Piperazines / Q000009:adverse effects*; D012559:Schizophrenia / Q000188:drug therapy; D013844:Thiazoles / Q000009:adverse effects*
D014150:Antipsychotic Agents; D010879:Piperazines; D013844:Thiazoles; C092292:ziprasidone